Dicerna raises $40M in follow-on

RNA therapeutics play Dicerna (NASDAQ:DRNA) raised $40 million through the sale of 5.7 million shares at $7 in a follow-on underwritten by Stifel, Evercore ISI, H.C. Wainwright and SunTrust. The price is an 11% discount to Dicerna's close at $7.84 on Dec. 13, when it proposed the offering after market close.

This month, Dicerna began a U.K. Phase I trial of lead candidate DCR-PHXC to treat primary hyperoxaluria. Proof-of-concept data are expected in 2H18. ...